Advertisement

Current Geriatrics Reports

, Volume 6, Issue 3, pp 139–148 | Cite as

Breast Cancer Care in the Elderly Patient

  • Grace Martin
  • Elizabeth ShaughnessyEmail author
Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Surgical Care for the Geriatric Patient

Abstract

Purpose of Review

As women continue to live longer, physicians adapt to treating well-described diseases such as breast cancer. Here we provide a comprehensive evidence-based review of the treatment of breast cancer in the elderly patient.

Recent Findings

Previous studies conducted to determine optimal treatment for breast cancer have primarily included younger, healthier women. Despite favorable tumor biology, older women are less likely to receive standard of care treatments relative to breast reconstruction, postoperative radiation, and adjuvant chemotherapy. Frailty is cited as a reason for not offering or receiving therapies. There are no strict definitions of frailty for this specific population, but there are general guidelines for older cancer patients, with a lower specificity than desired.

Summary

Treatment recommendations for older women vary little from those for younger women. However, the paucity of data for the older age group within trials raises the question of the basis of evidence. Risks of treatment need to be evaluated relative to life expectancy.

Keywords

Breast cancer Frailty Elderly Older Surgical treatment Adjuvant treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Elizabeth Shaughnessy and Grace Martin declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    The World Bank, World Development Indicators. Life expectancy at birth, total (years) | Data. 2017. In : Data.worldbank.org. http://data.worldbank.org/indicator/SP.DYN.LE00.IN. Accessed 9 Feb 2017.
  2. 2.
    Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92. doi: 10.1001/jama.285.7.885.CrossRefPubMedGoogle Scholar
  3. 3.
    Hamnett KE, Subramanian A. Breast reconstruction in older patients: a literature review of the decision-making process. J Plast Reconstr Aesthet Surg. 2016;69:1325–34. doi: 10.1016/j.bjps.2016.06.003.CrossRefPubMedGoogle Scholar
  4. 4.
    American Cancer Society. Cancer facts & figures 2017. 2017. In: Cancer.org. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. Access 9 Feb 2017.
  5. 5.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Pettke E, Ilonzo N, Ayewah M, Tsantes S, Estabrook A, Ma AMT. Short-term, postoperative breast cancer outcomes in patients with advanced age. Am J Surg. 2016;212:677–81. doi: 10.1016/j.amjsurg.2016.06.007. Thorough overview of the likely postoperative complication risks in the elderly with breast cancer, using the National Surgical Quality Improvement Program database CrossRefPubMedGoogle Scholar
  7. 7.
    Balducci L. Management of cancer in the elderly. Oncology, 1 Feb 2006, p 135. Expanded Academic ASAP, go.galegroup.com/ps/i.do?p=EAIM&sw=w&u=ucinc_main&v=2.1&id=GALE%7CA142723166&it=r&asid=43bf8457e578a9a35d77fc26933e3eb4.ist 2000;5:224–237. Accessed 9 Feb 2017.
  8. 8.
    Struck AE, Siu AL, Weiland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6. doi: 10.1016/0140-6736(93)92884-V.CrossRefGoogle Scholar
  9. 9.
    Bellera CA, Raingray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evalution of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. doi: 10.1093/annonc/mdr587.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Petit-Monegar A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pelissier S. Detection of frailty in elderly cancer patients: improvement of the G8 screening test. J Geriatric Oncol. 2016;7:99–107. doi: 10.1016/j.jgo.2016.01.004. A practical, short assessment of frailty among patients 70 years of age and older CrossRefGoogle Scholar
  11. 11.
    Weiss A, Noorbakhsh A, Tokin C, Chang D, Blair SL. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Ann Surg Oncol. 2013;20:3274–3278. Erratum in: Ann Surg Oncol 2014:21:S785. doi: 10.1245/s10434-013-3115-2.CrossRefPubMedGoogle Scholar
  12. 12.
    Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;12:e148–60. doi: 10.1016/S1470-2045(11)70383-7.CrossRefGoogle Scholar
  13. 13.
    Angarita FA, Chesney T, Elser C, Mulligan AM, McCready DR, Escallon J. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol. 2015;41:625–34. doi: 10.1016/j.ejso.2015.01.02.028.CrossRefPubMedGoogle Scholar
  14. 14.
    Cyr A, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA. Breast cancer in elderly women (≥80 years): variation in standard of care? J Surg Oncol. 2011;103:201–6. doi: 10.1002/jso.21799.CrossRefPubMedGoogle Scholar
  15. 15.
    Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106 doi: 10.1093/jnci/dju055.
  16. 16.
    Hadj P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, et al. Compliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol. 2014;25:372–7. doi: 10.1093/annonc/mdt513.CrossRefGoogle Scholar
  17. 17.
    Freedman RA, Vaz-Luis I, Barry WT, Li H, Lin NU, Winer EP, et al. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014;145:491–501. doi: 10.1007/s10549-014-2968-9.CrossRefPubMedGoogle Scholar
  18. 18.
    Van de Water W, Bastiaannet E, Dekkers OM, de Craen AJ, Westendoop RG, Voogd AC, et al. Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg. 2012;99:813–20. doi: 10.1002/bjs.8743.CrossRefPubMedGoogle Scholar
  19. 19.
    Wallweiner CW, Hartkopf AD, Grabe E, Wallweiner M, Taran FA, Fehm T, et al. Adjuvant chemotherapy in elderly patients with primary breast cancer: are women ≥65 undertreated? J Cancer Res Clin Oncol. 2016;142:1847–53. doi: 10.1007/200432-016-2194-4.
  20. 20.
    Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol. 2013;2013:893104. doi: 10.1155/2013/893104.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25:1858–69. doi: 10.1200/JCO.2006.10.4208.CrossRefPubMedGoogle Scholar
  22. 22.
    Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–6. doi: 10.1093/jnci/192.7.550.CrossRefPubMedGoogle Scholar
  23. 23.
    Pierga JY, Girre V, Laurence V, Asselain B, Die’ras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast. 2004;13:369–75. doi: 10.1016/j.breast.2004.04.012.CrossRefPubMedGoogle Scholar
  24. 24.
    NCCN clinical practice guidelines in oncology (NCCN Guidelines), Breast Cancer. Version 1.2016. J Natl Compr Cancer Network 2016:14:324–354.Google Scholar
  25. 25.
    Kemeny MM. Surgery in older patients. Semin Oncol. 2004;31:175–84. doi: 10.1053/j.seminoncol.2003.12.028.CrossRefPubMedGoogle Scholar
  26. 26.
    Fisher B, Anderson S, Bryant J, Margolese R, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus radiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41. doi: 10.1056/NEJMoa022152.CrossRefPubMedGoogle Scholar
  27. 27.
    Lichter AS, Lippman ME, Danforth DN Jr, d’Angelo T, Steinberg SM, deMoss E, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83. doi: 10.1200/jco.1992.10.6.976.CrossRefPubMedGoogle Scholar
  28. 28.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32. doi: 10.1056/NEJMoa020989.CrossRefPubMedGoogle Scholar
  29. 29.
    Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs. mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149:267–74. doi: 10.1001/jamasurg.2013.3049.CrossRefPubMedGoogle Scholar
  30. 30.
    Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119:1402–11. doi: 10.1002/cncr.27795.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hofvind S, Holen AT, Roman M, Sebuodegard S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41:1417–22. doi: 10.1016/j.ejso.2015.07.002.CrossRefPubMedGoogle Scholar
  32. 32.
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7. doi: 10.1056/NEJM199120303412706.CrossRefPubMedGoogle Scholar
  33. 33.
    • Mamtani A, Gonzalez JJ, Neo D, Slanetz P, Houlihan MJ, Herold C, et al. Early-stage breast cancer in the octagenarian: tumor characteristics, treatment choices, and clinical outcomes. Ann Surg Oncol. 2016;23:3371–8. doi: 10.1245/s10434-016-5368-z. Good overview of the tumor types relative to outcomes in the elderly breast cancer patient CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33. doi: 10.1097/SLA.0b013e3181f08f32.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. doi: 10.1016/s1470-2045(10)70207-2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection vs. axillary dissection. J Surg Oncol. 2010;102:111–8. doi: 10.1002/jso.21535.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Martelli G, Borachi P, Ardoino I, Lozza L, Behm S, Vetrella G, et al. Axillary dissection vs. no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920–4. doi: 10.1097/SLA.0b013e31827660a8.CrossRefPubMedGoogle Scholar
  38. 38.
    International Breast Cancer Study Group, Rudenstam C-M, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24:337–44. doi: 10.1200/JCO.2005.01.5784.CrossRefGoogle Scholar
  39. 39.
    Fenlon D, Frankland J, Foster CL, Brooks C, Coleman P, Payne S, et al. Living into old age with the consequences of breast cancer. Eur J Oncol Nurs. 2013;17:311–6. doi: 10.1016/j.ejon.2012.08.004.CrossRefPubMedGoogle Scholar
  40. 40.
    Song D, Slater K, Papsdorf M, VanLaeken N, Zhong T, Hazen A, et al. Autologous breast reconstruction in women older than 65 years versus women younger than 65 years: a multi-center analysis. Ann Plast Surg. 2016;76:155–63. doi: 10.1097/sap.0000000000000527.CrossRefPubMedGoogle Scholar
  41. 41.
    Andreae MH, Andreae DA. Regional anaesthesia to prevent chronic pain after surgery: a Cochrane systematic review and meta-analysis. Br J Anaesth. 2013;111:711–20. doi: 10.1093/bja/aet213.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Brit J of Anaesth. 2010;105:842–852. Erratum in: Br J Anaesth 2013:111:522. doi: 10.1093/bja/aeq265.CrossRefGoogle Scholar
  43. 43.
    Sato M, Shirakami G, Fukuda K. Comparison of general anesthesia and monitored anesthesia care in patients undergoing breast cancer surgery using a combination of ultrasound-guided thoracic paravertebral block and local infiltration anesthesia: a retrospective study. J Anesth. 2015;30:244–51. doi: 10.1007/s00540-015-2111-z.CrossRefPubMedGoogle Scholar
  44. 44.
    Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7. doi: 10.1056/NEJMoa040587.CrossRefPubMedGoogle Scholar
  45. 45.
    • Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7. doi: 10.1200/JCO.2012.45.2615. Use of radiotherapy in women over the age of 70 with breast cancer resected with lumpectomy and whether radiation improves survival CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106. doi: 10.1016/S0140-6736(05)67887-7.CrossRefPubMedGoogle Scholar
  47. 47.
    LeMasters T, Madhavan S, Sambamoorthi U. Comparison of the initial local-regional treatment received for early-stage breast cancer, between elderly women in Appalachia and a United States-based population: good and bad news. Glob J Breast Cancer Res. 2016;4:10–9. doi: 10.20941/2309-4419.2016.04.2.CrossRefGoogle Scholar
  48. 48.
    Shaitelman SF, Lin HY, Smith BD, Shen Y, Bedrosian I, Marsh GD, et al. Practical implications of the publication of consensus guidelines by the American Society for Radiation Oncology: accelerated partial breast irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2016;94:338–48. doi: 10.1016/j.ijrobp.2015.10.059.CrossRefPubMedGoogle Scholar
  49. 49.
    Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98:681–90. doi: 10.1093/jnci/djj/86.CrossRefPubMedGoogle Scholar
  50. 50.
    Shen X, Anne PR, Keith SW, Wojcieszynski A, Mishra MV, Bar-Ad V, et al. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer. Am J Clin Oncol. 2014;37:241–7. doi: 10.1097/coc.0b013e318271b326.CrossRefPubMedGoogle Scholar
  51. 51.
    van de Water W, Bastiaannet E, Scholten AN, Kiderlen M, de Craen AJ, Westendorp RG, et al. Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:786–94. doi: 10.1245/s10434-013-3374-y.CrossRefPubMedGoogle Scholar
  52. 52.
    Mogel HD, Clark C, Dodson R, Fino N, Howard-McNatt M. Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol. 2016:1–8. doi: 10.1245/e10434-016-5582-8.
  53. 53.
    Nagar H, Yan W, Christos P, Chao KS, Nori D, Ravi A. Older patients with early-stage breast cancer: adjuvant radiation therapy and predictive factors for cancer-related death. Am J Clin Oncol. 2014; doi: 10.1097/coc.0000000000000144.CrossRefGoogle Scholar
  54. 54.
    Daugherty E, Daugherty M, Bogart J, Shapiro A. Adjuvant radiation improves survival in older women following breast-conserving surgery for estrogen receptor negative breast cancer. Clin Breast Cancer. 2016;16:500–6. doi: 10.1016/j.clbc.2016.06.17.CrossRefPubMedGoogle Scholar
  55. 55.
    Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522–7. doi: 10.1200/JCO.2006.10.2749.CrossRefPubMedGoogle Scholar
  56. 56.
    Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–64. doi: 10.1200/JCO.2005.03.6053.CrossRefPubMedGoogle Scholar
  57. 57.
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6. doi: 10.1200/JCO.2005.02.3028.CrossRefPubMedGoogle Scholar
  58. 58.
    Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012;30:2218–26. doi: 10.1200/JCO.2011.38.5740.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Senkus E, Kyriakides S, Penault-Llorca F, Ohno S, Penault-Llorca F, Poortmans P, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30. doi: 10.1093/annonc/mdu298.CrossRefPubMedGoogle Scholar
  60. 60.
    Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055–2065. Erratum in N Engl J Med 2009:361:1714. doi: 10.1056/NEJMoa0810266.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015;121:3639–48. doi: 10.1002/cncr.29506.CrossRefGoogle Scholar
  62. 62.
    von Minckwitz G, Reimer T, Potenberg J, Conrad B, Schurer U, Eidtmann H, et al. The phase III ICE study: adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Res. 2015;75:S3–04. doi: 10.1158/1538-7445.SABCS14.S3-04.CrossRefGoogle Scholar
  63. 63.
    Sun J, Chia S. Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. Br J Cancer. 2017;116:4–9. doi: 10.1038/bjc.2016.360.CrossRefPubMedGoogle Scholar
  64. 64.
    Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7 year followup of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–83. doi: 10.1200/JCO.2008.18.4028.CrossRefPubMedGoogle Scholar
  65. 65.
    Owusu C, Lash TL, Silliman RA. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J. 2007;13:374–82. doi: 10.1111/j.1524-4741.2007.00445.x.CrossRefPubMedGoogle Scholar
  66. 66.
    Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70. doi: 10.1056/NEJMoa040595.CrossRefPubMedGoogle Scholar
  67. 67.
    Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs. tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer. 2007;96:1025–9. doi: 10.1038/sj.bjc.6603600.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Colleoni M, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29:1117–24. doi: 10.1200/JCO.2008.17.0829.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Arimidex T, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, Howell A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi: 10.1016/S1470-2045(07)70385-6.CrossRefGoogle Scholar
  70. 70.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA 17 trial of extended adjuvant letrozole. Ann Oncol. 2013;24:355–61. doi: 10.1093/annonc/mds330.CrossRefPubMedGoogle Scholar
  71. 71.
    Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 + early breast cancer patients. Cancer Res. 2016;76:S5–04. doi: 10.1158/1538-7445.SABCS15-S5-04.CrossRefGoogle Scholar
  72. 72.
    Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39:44–50. doi: 10.1016/jctrv.2012.03.009.CrossRefPubMedGoogle Scholar
  73. 73.
    Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31:4222–8. doi: 10.1200/JCO.2013.48.7884.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28:3416–21. doi: 10.1200/JCO.2009.23.6950.CrossRefPubMedGoogle Scholar
  75. 75.
    Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, et al. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer. 2013;119:839–46. doi: 10.1002/cncr.27831.CrossRefPubMedGoogle Scholar
  76. 76.
    Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32:927–34. doi: 10.1007/s10549-014-2668-9.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Col Cardiol. 2012;60:2504–12. doi: 10.1016/j.jacc.2012.07.068.CrossRefGoogle Scholar
  78. 78.
    • Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, et al. Treatment of older patients with HER@-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013;142:89–99. doi: 10.1007/s10549-013-2710-z. Analysis of the subset of elderly patients in the pivotal CLEOPATRA trial CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Loibl S, Jackisch C, Schneeweiss A, Schmatioch S, Aktas B, Denkert C, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2016;Google Scholar
  80. 80.
    Gianni L, Penkowski T, Im YH, Tseng LM, Liu MC, Lluch AS, et al. 5-year analysis of neodjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicenter, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791–800. doi: 10.1016/S1470-2045(16)00163-7.CrossRefGoogle Scholar
  81. 81.
    Smyth LM, Iyengar NM, Chen MF, Popper SM, Patail S, Wasserheit-Lieblich C, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat. 2016;158:91–7. doi: 10.1007/s10549-016-3851-7.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016;18:126. doi: 10.1186/s13058-016-0773-6.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65. doi: 10.1200/JCO.2011.34.7625.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    • Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86. doi: 10.1002/cncr.26646. Helpful in choosing whether to initiate chemotherapy in the treatment of the elderly patient with breast cancer CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations